Surface Oncology Inc SURF:NASDAQ

Last Price$3.72NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$3.71 (2)
Ask (Size)$3.85 (1)
Day Low / HighN/A - N/A
Volume662.0 K
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Surface Oncology Inc ( NASDAQ )

Price: $3.72
Change: -0.21 (5.34%)
Volume: 662.0 K
4:00PM ET 1/21/2022
 
 

ZIOPHARM Oncology Inc ( NASDAQ )

Price: $0.82
Change: -0.04 (5.11%)
Volume: 2.0 M
4:00PM ET 1/21/2022
 
 

Harpoon Therapeutics Inc ( NASDAQ )

Price: $5.09
Change: -0.08 (1.55%)
Volume: 228.5 K
4:00PM ET 1/21/2022
 
 

Molecular Templates Inc ( NASDAQ )

Price: $3.14
Change: -0.12 (3.68%)
Volume: 176.9 K
4:00PM ET 1/21/2022
 
 

Matinas BioPharma Holdings Inc ( NYSE MKT LLC )

Price: $0.82
Change: -0.03 (3.62%)
Volume: 1.4 M
6:30PM ET 1/21/2022
 

Read more news Recent News

Surface Oncology Names Denice Torres as Chair of Board of Directors
7:43AM ET 12/15/2021 MT Newswires

Surface Oncology (SURF) said Wednesday it appointed Denice Torres as chair of the board of directors. Torres has been a board member of the company since...

Surface Oncology Gets US FDA Clearance for Human Clinical Trial of Potential Anti-Tumor Therapy
8:39AM ET 12/01/2021 MT Newswires

Surface Oncology (SURF) said Wednesday the US Food and Drug Administration has cleared the company's investigational new drug application for its...

-- Earnings Flash (SURF) SURFACE ONCOLOGY Posts Q3 Revenue $392,000
7:18AM ET 11/04/2021 MT Newswires

...

Surface Oncology to Study Potential Antibody's Use For Treatment-Naive Hepatocellular Carcinoma
8:55AM ET 10/04/2021 MT Newswires

Surface Oncology (SURF) on Monday announced plans to start a randomized Phase 2 clinical study evaluating its SRF388 potential antibody against IL-27 in...

View all Commentary and Analysis

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
8:00AM ET 1/18/2022 Seeking Alpha

Surface Oncology: Staying The Course
7:44PM ET 10/24/2021 Seeking Alpha

Surface Oncology (SURF) Investor Presentation - Slideshow
4:30PM ET 8/13/2021 Seeking Alpha

Surface Oncology: A Diverse, But Early Pipeline
9:20PM ET 7/12/2021 Seeking Alpha

Company Profile

Business DescriptionSurface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also include licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. View company web site for more details
Address50 Hampshire Street
Cambridge, Massachusetts 02139
Phone+1.617.714.4096
Number of Employees76
Recent SEC Filing01/14/20224
President, Chief Executive Officer & DirectorRobert W. Ross
Chief Financial OfficerJessica Fees
Chief Scientific OfficerVito J. Palombella
Chief Medical OfficerAlison M. O'Neill

Company Highlights

Price Open$3.98
Previous Close$3.93
52 Week Range$3.71 - 13.90
Market Capitalization$171.6 M
Shares Outstanding46.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings12.00
Earnings per Share$0.31
Beta vs. S&P 500N/A
Revenue$59.4 M
Net Profit Margin14.33%
Return on Equity8.69%

Analyst Ratings as of 05/14/2021

Buy
5
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset